Marshall Wace’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-100
Closed -$77.2K 3605
2025
Q4
$77.2K Sell
100
-1,300
-93% -$883K ﹤0.01% 2739
2025
Q3
$787K Buy
+1,400
New +$792K ﹤0.01% 2045
2025
Q2
Sell
-36,500
Closed -$23.1M 3081
2025
Q1
$23.1M Buy
+36,500
New +$25.1M 0.03% 479
2021
Q4
Sell
-13,900
Closed -$8.41M 4215
2021
Q3
$8.41M Buy
+13,900
New +$8.63M 0.03% 652

Other funds holding REGN

Marshall Wace's REGN Position: Q2 2026 in Review

Marshall Wace increased its Regeneron Pharmaceuticals (REGN) stake by 6,416% in Q2 2026, buying an estimated $15.4M and bringing the position to 23,000 shares worth $14.3M. The position accounts for 0.01% of the portfolio, ranked #877.

Marshall Wace first reported a position in REGN in Q2 2014 and has held it in 38 quarters since. The position peaked at $369M in Q4 2025. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Marshall Wace held 23,000 shares of Regeneron Pharmaceuticals worth $14.3M as of Q2 2026.
  • Marshall Wace bought 22,647 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $15.4M.
  • Regeneron Pharmaceuticals made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #877 holding.
  • Marshall Wace first reported a position in Regeneron Pharmaceuticals in Q2 2014 and has held it in 38 quarters since.
  • Marshall Wace's Regeneron Pharmaceuticals position peaked at $369M in Q4 2025.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.